142 filings
10-Q
2024 Q1
HUMA
Humacyte Inc
Quarterly report
13 May 24
4:11pm
8-K
HUMA
Humacyte Inc
10 May 24
Humacyte First Quarter 2024 Financial Results and Business Update
7:06am
DEFA14A
HUMA
Humacyte Inc
29 Apr 24
Additional proxy soliciting materials
7:16am
DEF 14A
HUMA
Humacyte Inc
Definitive proxy
29 Apr 24
7:12am
S-8
HUMA
Humacyte Inc
28 Mar 24
Registration of securities for employees
8:55am
8-K
wzuh9ui 0c
22 Mar 24
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
7:06am
8-K
yp2rnsizmfgq50r3
4 Mar 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
6:53am
424B5
k9iogizppn5ija
1 Mar 24
Prospectus supplement for primary offering
4:05pm
424B5
79egdqo
29 Feb 24
Prospectus supplement for primary offering
4:11pm
8-K
yr4uue imy6kly
29 Feb 24
Other Events
4:02pm
8-K
033yg6b7z36xvgc
9 Feb 24
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
8:06am
8-K
eg2qd3guic lrx5xix
12 Dec 23
Other Events
8:06am
8-K
qg77711vq21k53di lb0
9 Nov 23
Humacyte Third Quarter 2023 Financial Results and Business Update
4:07pm
8-K
c0j3mgavl
12 Sep 23
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
7:09am
8-K
jaksec7
14 Aug 23
Humacyte Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
g5r2n0w7 ap6b
26 Jul 23
Humacyte Completes Enrollment in Phase 2/3 Trial of
8:07am
424B3
ddasf7jjik69 00tr7
22 Jun 23
Prospectus supplement
6:50am